![]() |
市场调查报告书
商品编码
1399642
单纯疱疹病毒治疗市场 - 依病毒类型(HSV-1、HSV-2)、药物类型(阿昔洛韦、伐昔洛韦)、部位(口服、生殖器)、给药途径(口服、局部)、配销通路(医院、零售) , 全球预测,2023-2032Herpes Simplex Virus Treatment Market - By Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir), Site (Oral, Genital), Route of Administration (Oral, Topical), Distribution Channel (Hospital, Retail), Global Forecast, 2023-2032 |
由于治疗方法的进步、人们对疱疹感染的认识不断提高以及单纯疱疹病毒-2 (HSV-2) 患病率的不断上升,全球单纯疱疹病毒(HSV) 治疗市场预计在2023 年至2032 年期间将以4% 的速度成长。2)。
根据世界卫生组织 2023 年的报告,全球 50 岁以下人口中约 67%(37 亿)患有 1 型单纯疱疹病毒 (HSV-1),导致口腔疱疹。据估计,15-49 岁人群中的 13%(4.91 亿)患有 2 型单纯疱疹病毒 (HSV-2),从而导致生殖器疱疹。许多单纯疱疹病毒感染是无症状的或未被识别。随着公众意识的不断增强,人们对疱疹病毒的性质、传播和潜在併发症的了解越来越多。对早期诊断和适当治疗的关注促进了对先进治疗解决方案的需求。
全球单纯疱疹病毒(HSV)治疗产业根据病毒类型、药物类型、部位、给药途径、配销通路和地区进行分类。
由于 HSV-2 病毒类型在全球人口中的盛行率不断上升,预计在研究期间将持续成长。专注于解决 HSV-2 带来的具体挑战的研发活动激增,强调需要针对这种疱疹病毒株独特特征的专门治疗方案。
由于伐昔洛韦药物类型能够透过抑制病毒复製来控制疱疹感染,因此预计到 2032 年将实现稳定成长。作为阿昔洛韦的前药,伐昔洛韦可增强生物利用度并确保延长抗病毒活性,进而抑制感染。此外,该药物对 HSV-1 和 HSV-2 均有效,使其成为临床医生和患者的首选。
由于疱疹感染盛行率激增,预计亚太地区单纯疱疹病毒 (HSV) 治疗市场规模将在 2023 年至 2032 年快速扩张,因此需要更加关注治疗和管理策略。中国和印度等国家的医疗基础设施正在取得显着进展。此外,人们对性传染感染的认识不断增强,这增加了对有效的疱疹治疗解决方案的需求。该地区有利的医疗保健政策将塑造未来几年的产业动态。
The global Herpes Simplex Virus (HSV) treatment market is expected to register a 4% growth rate during 2023-2032, propelled by advancements in therapeutic approaches, rising awareness about herpes infections, and a growing prevalence of Herpes Simplex Virus-2 (HSV-2).
As per a WHO report in 2023, about 67% of the global population aged below 50 years (3.7 billion) have herpes simplex virus type 1 (HSV-1), causing oral herpes. An estimated 13% of people aged 15-49 years (491 million) has herpes simplex virus type 2 (HSV-2), leading to genital herpes. Many HSV infections are asymptomatic or go unrecognized. As public awareness builds overtime, individuals are becoming more informed about the nature, transmission, and potential complications associated with herpes viruses. The focus on early diagnosis and appropriate treatments is contributing to the demand for advanced therapeutic solutions.
The global Herpes Simplex Virus (HSV) treatment industry is classified based on virus type, drug type, site, route of administration, distribution channel, and region.
The HSV-2 virus type segment is expected to witness sustained growth during the study period driven by its rising prevalence amongst the global population. There is a surge in R&D activities focused on addressing the specific challenges posed by HSV-2, emphasizing the need for specialized treatment options catering to the unique characteristics of this herpes strain.
The valacyclovir drug type segment is set for steady growth through 2032 owing to its efficacy in managing herpes infections by inhibiting viral replication. As a prodrug of acyclovir, valacyclovir enhances bioavailability and ensures prolonged antiviral activity, thereby curbing the infection. Moreover, the drug is effective against both HSV-1 and HSV-2, making it a preferred choice for clinicians and patients alike.
Asia Pacific Herpes Simplex Virus (HSV) treatment market size is anticipated to witness rapid expansion over 2023-2032, driven by a surge in the prevalence of herpes infections, necessitating increased attention to treatment and management strategies. Countries like China and India are experiencing notable advancements in healthcare infrastructure. Also, there is a growing awareness of sexually transmitted infections, contributing to the demand for effective herpes treatment solutions. The favourable healthcare policies in the region will shape the industry dynamics in the coming years.